AQR Capital Management
RYTM icon

AQR Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

AQR Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.57M Sell
59,208
-71
-0.1% -$6.42K ﹤0.01% 1827
2026
Q1 		$5.16M Sell
59,279
-10,767
-15% -$1.05M ﹤0.01% 1723
2025
Q4 		$7.5M Sell
70,046
-9,734
-12% -$1.03M ﹤0.01% 1347
2025
Q3 		$8.06M Buy
79,780
+30,740
+63% +$2.85M 0.01% 1193
2025
Q2 		$3.1M Buy
49,040
+9,677
+25% +$593K ﹤0.01% 1533
2025
Q1 		$2.09M Buy
39,363
+23,506
+148% +$1.3M ﹤0.01% 1584
2024
Q4 		$888K Sell
15,857
-16,952
-52% -$936K ﹤0.01% 1949
2024
Q3 		$1.72M Sell
32,809
-71,021
-68% -$3.4M ﹤0.01% 1573
2024
Q2 		$4.26M Buy
103,830
+32,831
+46% +$1.31M 0.01% 1093
2024
Q1 		$3.08M Buy
70,999
+56,017
+374% +$2.45M 0.01% 1220
2023
Q4 		$689K Sell
14,982
-5,314
-26% -$168K ﹤0.01% 1749
2023
Q3 		$465K Buy
20,296
+7,580
+60% +$170K ﹤0.01% 1873
2023
Q2 		$210K Buy
+12,716
New +$230K ﹤0.01% 2070
2022
Q3 		– Sell
-10,295
Closed -$43K – 2305
2022
Q2 		$43K Buy
10,295
+164
+2% +$898 ﹤0.01% 2141
2022
Q1 		$117K Buy
+10,131
New +$88.9K ﹤0.01% 2127
2021
Q4 		– Sell
-10,191
Closed -$133K – 2267
2021
Q3 		$133K Buy
+10,191
New +$156K ﹤0.01% 2188

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AQR Capital Management's RYTM Position: Q2 2026 in Review

AQR Capital Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 0.12% in Q2 2026, selling an estimated $6.42K and leaving 59,208 shares worth $6.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

AQR Capital Management first reported a position in RYTM in Q3 2021 and has held it in 16 quarters since. The position peaked at $8.06M in Q3 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • AQR Capital Management held 59,208 shares of Rhythm Pharmaceuticals worth $6.57M as of Q2 2026.
  • AQR Capital Management sold 71 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $6.42K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1827 holding.
  • AQR Capital Management first reported a position in Rhythm Pharmaceuticals in Q3 2021 and has held it in 16 quarters since.
  • AQR Capital Management's Rhythm Pharmaceuticals position peaked at $8.06M in Q3 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.